Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today
Stocks generally disappointed investors on Friday as the Ukrainian situation trumped strong jobs data, but these three stocks performed much worse than the broader market. Find out why.
Why Seattle Genetics, Inc. Shares Soured
Seattle Genetics shares sink despite topping Wall Street's expectations in the first quarter. See what has investors up in arms and what you should do about it.
Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth
Antibody-drug conjugate developer Seattle Genetics delivers strong sales gains from lead drug Adcetris despite a flat year-over-year net loss.